An open-label, phase III study to evaluate the efficacy and safety of MRA [tocilizumab] in patients with RA [rheumatoid arthritis]

Trial Profile

An open-label, phase III study to evaluate the efficacy and safety of MRA [tocilizumab] in patients with RA [rheumatoid arthritis]

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2016

At a glance

  • Drugs Disease-modifying antirheumatics; Tocilizumab
  • Indications Rheumatoid arthritis
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms SAMURAI
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 01 Sep 2007 Results have been published.
    • 01 Sep 2007 Trail name and acronym added.
    • 13 Aug 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top